Remove 2021 Remove Drug Development Remove Life Science Remove Remote care
article thumbnail

Where are HealthTech's soft landing M&A deals in today's market?

Lloyd Price

Market Dynamics: Lower valuations: Compared to the heady days of 2021, HealthTech valuations have cooled down, making "soft landing" deals more attractive for both acquirers and targets. Pharmaceutical and Life Sciences Companies: These companies are looking for HealthTech solutions to: Enhance clinical trials and drug development processes.